In recent years, the dysfunction of the haemostatic system in relation to the clinical complications from arterioscleroses and cardiovascular diseases has become more recognised. Blood coagulation and fibrinolysis comprise two important physiological systems, which are regulated by a balance between activators and inhibitors. Activation of blood coagulation is associated with accelerated clot f...

Purpose – determine the characteristics of changes procoagulant, anticoagulant and fibrinolytic links hemostatic system in patients with hypertension combination coronary heart disease.
 Materials methods. 127 people were examined - 14 healthy (control), 61 stage II concomitant disease (group 2), 52 hypertensive III 3). There evaluated indicators hemostasis system: thrombin time, activated...

The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid-liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as i...

The objective of this multicentre study was to identify the concentrations of cardiac troponin I having a higher probability of cardiovascular and extracardiovascular complications in patients with acute myocardial infarction that were treated with or without fibrinolysis at the intensive care units. These patients were followed for 10 days and divided into two prognostic groups: one without co...

BACKGROUND Timely reperfusion after ST-elevation myocardial infarction (STEMI) improves survival. Guidelines recommend primary percutaneous coronary intervention (PPCI) within 90 minutes of arrival at a PCI-capable hospital. The alternative is fibrinolysis within 30 minutes for those in those for whom timely transfer to a PCI-capable hospital is not feasible. METHODS AND RESULTS We identified...

CUTE HYPOFIBRINOGENEMIA may result from systemic intravascular coagulation ( defibrination ),or from spontaneous pathologic fibninolysis, or both. The pathogenesis of these conditions has been ascribed to the local release of thromboplastic substances,1’2 or fibrinolytic substances34 or a cornbination of these.5’6’7 Since either thromboplastic or fibrinolytic substances may reduce the level of ...

BACKGROUND AND PURPOSE Although intra-arterial (IA) fibrinolysis for acute ischemic stroke has been clinically available for many years, it is not a therapy approved by the US Food and Drug Administration. Single, randomized, clinical trials (RCTs) have suggested beneficial effects, but no single RCT has demonstrated that IA fibrinolysis yields increases in both good (modified Rankin Scale scor...